Biocompatibles Share Discussion Threads

[tratante] 09/11/2010 17:23

wonder if we will get news tomorrow. No basis, just a feeling.

[tratante] 05/11/2010 09:23

mms trying to make a bit of money in the lull, trigger a few sales, more stock for them to sell at a higher price when the bid comes in?

[spyder] 05/11/2010 07:25

Hi oldtown
I had wondered about whether the Nomura appointment might indicate the appearance of additional interest, but I did not want to tempt fate by suggesting it. Damn! Now I have gone and done it!!
The large sales at 325p are really perplexing at this stage of the game, unless the numbers were reported back to front! :-)

[oldtown] 04/11/2010 22:32

The Nomura Code boys specialize in Pharma companies and specifically Japanese matters, maybe a new bidder from Japan has entered the frame at the last fence?
They are also known for placings and fundraisings, but with the cash the company has i don't know if that's the case here.
I really don't know enough about BII these days to make a informed comment.

[tratante] 04/11/2010 21:26

surely they wouldn't let it go so cheaply, 325 is not much higher than than before the bid was announced. In the article above one analyst values them at 520p. I trust the management not to give this company away - I hope it's not misplaced.

[spyder] 04/11/2010 19:57

I agree, it is very interesting to see the appointment of Nomura as (new/ additional?) corporate broker in the absence of any other news. What is even more surprising is the several large trades today at 325p .... who ever sold obviously thinks the deal is either off, or not worth much more than 325p and it would be odd to conclude the latter. It will be intersting to see who sold the shares.
I think we might be in for some more news soon ...

[tratante] 04/11/2010 17:34

speculation as to bidder, Bayer and others in the frame.

[tratante] 04/11/2010 17:21

...ah do people think that the change of broker indicates the deal may be off. If that were the case I think news about the deal would have come first.

[tratante] 04/11/2010 17:17

surprised to see the price fall when BII say negotiations are at an advanced stage. An announcement could come at any time.

[spyder] 01/11/2010 05:46

I missed the announcement about MoleMate last Friday - another hidden gem in the BII stable?

* New UK and Australia study, in 858 patients supports use of MoleMate in
the diagnosis of melanoma in primary care

* Statistically significant difference (p = 0.02) in diagnostic accuracy
against the current gold standard test for melanoma, in primary care

The Company estimates that MoleMate is in use in more than 200 primary care
clinics world-wide with more than 100 in Australia, over 30 in New Zealand and
that, including patients examined by private sector screening clinics, more
than 20,000 patients have been examined with MoleMate. MoleMate is CE Marked
and available throughout the EU and in other parts of the world, including
Australia and New Zealand. A different product built on the same technology
platform, MoleMate USA, is 510k cleared in the United States. Biocompatibles
is in the process of establishing a global distribution network.
Crispin Simon, Chief Executive of Biocompatibles, commented:

"The importance of early and accurate diagnosis are well known. Melanoma is
relatively easy to screen and typically fatal if detected late. This technology
delivers accurate results at an affordable cost in a location that is
convenient to patients. GPs are able to offer the patients a quick diagnosis,
relieving them of anxiety.

Referral patterns do not change quickly. This is a dangerous cancer and we need
both GPs and Dermatologists to be confident that the use of MoleMate in primary
care offers a clear benefit to patients. This paper is an important step in
this direction. But efficiency is the order of the day and the opportunity to
reduce the 88% of referred lesions, which turn out to be benign, now seems
pretty clear.

This paper is an important step forward for the technology and we look forward
to its commercialisation in the years ahead."

[tratante] 29/10/2010 10:24

yep a few first thing yesterday morning would be giving a tidy profit now.

[fenners66] 28/10/2010 17:40

Seems the market has woken up tto the idea with a start. Another missed buying opportunity!

[tratante] 28/10/2010 10:13

Excellent progress and solid statement. Takeover looks on, but surely for more than 350 per share.

[tratante] 20/10/2010 09:55

possibly caused by some impatience and uneasiness triggered by the Novabel announcement, although I suspect this is not a big issue for who ever is running the slide rule over BII, not the most exciting part of the company. Sometimes I've seen this kind of fall just before a positive announcement, mms see the opportunity to make some easy money. Like you Spyder, I trust the management to either sell for a considerable premium or hold on and let the co grow as an independent. Either way i would be happy. If I had the funds I might even top up, as it's almost at pre bid price and there is nothing to say that the bid might not come through.

[spyder] 20/10/2010 05:47

Yesterday's drop is rather extreme, but as always, on tiny volume.
Therein lies the problem with this share, it is very difficult to trade in any quantity other than on results days, even then it is not easy. Most of the investors are holders, not traders, and a takeover is the only realistic exit route for them. The question is, is now the right time to exit?
The confidence in the board to make the right decision is beyond doubt in my view, and they are best left to work through the process without distractions, but unfortunately yesterday's fall is rather unhelpful in that regard and might force an announcement.
As time went by, I was beginning to think that an offer might be accepted, I am surprised the trickle sellers thought otherwise.

[plutonian] 19/10/2010 17:06

Judging by recent trading it looks like some don't think the recent preliminary approach will amount to anything. Novabel problems were already known when the approach was made, so that should not put them off.

[fagine] 19/10/2010 15:12

product has been withdrawn see Friday 15th RNS

[greek islander] 19/10/2010 14:25

I've just noticed the huge drop in price - anyone care to explain?

[inki] 05/10/2010 18:02

Hunter Hall having increased their position, closer towards the 29.9% seems to show confidence either in a bid or in trading/progress.

[tratante] 23/9/2010 10:25

It would be a trevesty for BII to go so cheaply, it could have easily reached that price in a couple of months. The potential markets for their products is huge and they are on track in their development. Don't let this be a quick buck sellout - please!

[spyder] 23/9/2010 10:20

Hi all
The market report from the Times yesterday commented ... 'There was also confirmation from Biocompatibles International that it had been approached for a possible takeover. No price was mentioned but chunks of stock crossed at 355p, suggesting an approach in that region. The medical technology company rose 25.5p to 353p.'
There were two trades on Tuesday amounting to ~700,000 shares at 355p.
Surely any potential offer cannot be as low as 355p? I would certainly see that as a significant undervaluation of the potential future cash flow for this business, but the decision will rest in the hands of three institutional shareholders.
What would be really exciting is if more than one party showed an interest ...

[aim_trader] 22/9/2010 00:24

Crispin Simon , CEO of Biocompatibles, says it's targeting 1 million procedures globally of its Drug-Eluting Beads

"Crispin Simon, CEO of Biocompatibles tells Proactive Investors that its growth will come from a multiple increase in use of its drug eluting beads. It's looking at a global expansion which it anticipates will include new markets such as China to accompany its recent expansion into Brazil and Argentina."

[baronet 1] 21/9/2010 11:02

STOCKS NEWS EUROPE

Biocompatibles up on bid approach

21 September 2010 09:44:52

Shares in UK smallcap medical technology company Biocompatibles BII.L rise around 12 percent after it confirms a bid approach, having noted recent moves in its share price.

The firm is "attractive as a takeover candidate, having established market traction and momentum with its drug eluting bead franchise and some interesting projects in the pipeline," analysts at Nomura say in a note.

Biocompatibles is expected to post a maiden profit this year, they say, and a potential acquirer would need to offer a significant premium to Nomura's end-2010 fair value for the stock of 333 pence a share.

Possible suitors include

Terumo Corp 4543.T , Angiodynamics ANGO.O , SciClone Pharmaceuticals SCLN.O or BTG BGC.L , they add.


JB

[tratante] 21/9/2010 09:08

Quite agree APAD, fantastic company, great potential & already paying a divi - and a bulletin board pleasently free of froth and drongoes! If it's going, it better be for a substantial premium to current share price